Disease Landscape and Forecast Insights

Heart failure with reduced ejection fraction (HFrEF) has a well-established drug treatment with a wealth of supporting evidence from clinical trials. ACE inhibitors, or ARBs, beta blockers, and…

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases, and even though understanding of the disease’s pathophysiology has…

Chronic heart failure (CHF) is a long-term condition primarily managed by angiotensin-converting enzyme (ACE) inhibitors, oral beta blockers, or oral diuretics. The addition of a second- or third-…

Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease (PKD), is a genetic disorder in which fluid-filled cysts progressively develop in the kidney…

The multiple sclerosis (MS) therapy market continues to evolve, with each new food and drug administration approved disease-modifying therapy (DMT) further expanding treatment choices. The newest…

Although chemotherapy has traditionally been the cornerstone of ovarian cancer treatment, angiogenesis and PARP inhibitors have revolutionized the treatment landscape, impacting prescribing…

The renal cell carcinoma (RCC) therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens…

Chemotherapy is the backbone of treatment for colorectal cancer, but treatment in the metastatic setting has expanded with the approval of several targeted agents. Well-established targeted…

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) plus endocrine therapy are entrenched first-line…

Multiple well-established therapies are available to treat Crohn’s disease (CD). The mostly widely used biologics, the TNF-α inhibitors (e.g., Janssen / Merck’s Remicade, AbbVie / Eisai’s…

The arrival of newer and more effective treatments in the U.S. psoriasis market is changing the treatment landscape and fueling competition for favorable coverage from MCOs. After years of…

Dyslipidemia, characterized by abnormal lipid levels, plays a pivotal role in the development of cardiovascular (CV) disease. To address this risk factor, physicians use a range of lipid-modifying…